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INTRODUCTION 
 Siddha system of medicine is commonly practiced byTamilians of peninsular 
South India. Fundamental Principles of Siddha include theories of five elements 
(Aimpootham), and three humors (Mukkuttram). Siddha system of medicine not only 
includes polyherbal formulations, but also metals, chemicals, and/or animal products. 
The common Siddha preparations are parpam (calcined metals and minerals), 
Chenduram (red coloured powders), Churanam (powders), Kashayam (decoctions), 
Lehiyam (confections), Nei (ghee), Tailam (oil), and Mezhugu (wax)[1].Calomel-
containing preparations have been used extensively in siddha system of medicine for 
treatment of chronic ailments like syphilis, high fever, pneumonia, insomnia, nervous 
disorders,deafness, and paralysis of the tongue. Contrary to Western medicine, which 
does not promote the use ofmercury due to its toxic effects, Siddha medical 
practitioners believe that mercury-based formulations have potent therapeutic 
efficacy, while there is no toxicity due to the unique and repeated purification 
processes employed during preparation. 
However, lack of proper pharmacovigilance and widespread self-medication 
has resulted in undesirable effects to certain sections of the consumers of these 
preparations, which have contributed to the negative publicity for these forms of 
medicine. Variations in the quality of the preparations coupled with the lack of 
understanding of the differences in the recommended dosages and treatment strategies 
adopted by traditional medicine practitioners, further fuels concerns in the Western 
world on the safety and efficacy of traditional medicine. But in spite of these 
concerns, concerted efforts to understand the biological interactions and 
transformations of these preparations are yet to gain momentum. Although scattered 
reports on the toxicity of these preparations are available in literature, their 
mechanism of action has not been conclusively established [2]. Long-term 
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pharmacotherapeutic and in-depth toxicity studies are needed to address the 
apprehensions raised by these herbo-metallic preparations. 
This research work aims in evaluating the toxicological effects of 
Pooraparpam(ர பப)- calomel derived drug in albino rats. Calomel was taken 
internally and used as a laxative and disinfectant, as well as in the treatment of 
syphilis, until the early 20th century. Until fairly recently it was also used as a 
horticultural fungicide, most notably as a root dip to help prevent the occurrence 
of clubroot amongst crops of the Brassicaceae family.[3] 
 Calomel was used by doctors in America throughout the 18th century, and 
during the revolution, to make patients regurgitate and release their body from 
"impurities". Benjamin Rushwas one particular well-known advocate of mercury in 
medicine and used calomel to treat sufferers of yellow fever during its outbreak 
in Philadelphia in 1793. Calomel was given to patients as a purgative or cathartic until 
they began to salivate and was often administered to patients in such great quantities 
that their hair and teeth fell out.[4] Shortly after yellow fever struck Philadelphia, the 
disease broke out in Jamaica. A war of words broke out in the newspapers concerning 
the best treatment for yellow fever; bleeding or calomel. Anecdotal evidence indicates 
calomel was more effective than bleeding.[5] 
Pooraparpam is a calomel-derived drug widely used in therapeutic 
management of various skin disorders, venereal diseases, metabolic disorders and 
menstrual disorders.  Its use has been described by many sages for treatment of 
various metabolic disorders including diabetes [6]. In siddha system of medicine 
calomel is used internally and externallyfor treatment of various genital cancers 
(லி0க
 1ம1 ேயான3
 1) and syphilitic ulcers ('ழி/ கிர தி) [6]. 
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Though there are lot of methods described by various sages for preparation of 
pooraparpam, preparation using piper beetle and crab extract described in 
Aruvaimaruthuvam is followed in this research work. 
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REVIEW OF LITERATURE: 
CALOMEL:  
 Mercury(I) chloride is the chemical compound with the formula Hg2Cl2. Also 
known as calomel (a mineral form, rarely found in nature). Mercurous chloride, this 
dense white or yellowish-white, odourless solid is the principal example of 
a mercury(I) compound.Various properties of calomel are shown in Table.2.1. 
Table 1: Properties of Calomel 
Properties 
Molecular formula Hg2Cl2 
Molar mass 472.09 g/mol 
Appearance White solid 
Density 7.150 g/cm3 
Melting point 525 °C (triple point) 
Boiling point 383 °C (sublimes) 
Solubility in water 0.2 mg/100 mL 
Solubility insoluble in ethanol, ether 
Refractive index 1.973 
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ர(இரச/கர) 
ரைவ – ெசைற 
1. பாடதி+ 16 வராகெனைட (627 கிரா) க தக ைவ!/கி, 80 
வரகெனைட(336 கிரா) இரசேச8!!ளாவ%/ெகாQ தா+, 
க1!வ%ப%ற'ேவெறாபாடதி+பாதி/':ெச0க+ெபாQைய

ேபா?, அத*ேம+அைர
பQ(650 மி.லி?ட8) கறிW
ைபைவ!, 
உ
ப%*ேம+ேமபQஇரசக திையைவ!, சீைலமெச!, 12 
மண%ேநரகாட/கின3யாஎG!எ!'ள38 தப%ற'ேம+பாட
ைத:சா/கிரைதயாந</கி
பா8தா+ரக?Qயா
பQ தி/'. 
 
ரதிைறக: 
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1. கமா1ெவறிைல, மிள'வைக/'கா+பல (8.75 கிரா) 
நி1ெத!:சிறி!ந<8வ%?அைர!, க+கைதஒபQ (1.3 
லி?ட8)ந<G+கல !ஒபல (35 கிரா) 
ரைத:சீைலய%+Q!!லாய திரமாந<G+அமிJபQெச!,. 
ந<8/காப0'Qயப%ற', 
ரைதஎ!ந<8வ%?/கJவ%ெவய%லி+உல8திஎ/கெவ. 
2. ஒபல (35 கிரா) 
ரதி'ைல
பாலினா+*1மண%ேநர/'/ெகா!ப%ற
'ெவைள
ைதலதினா+ஒ*ப!மண%ேநர/கி?எ
!/ெகாளH. 
3. இேலகிய0கள3+ேச8/கெவQயரைத /ைக: 
சாறினா+/கி?கJவH. 
      - 'ணபாடதா!ஜ<வவ'
 
4. இரச/கர 1 
பலஇதைனெம+லிய!ண%ய%+கிழிக?Q/ெகாளெவ. 
ஒமபாடதி+இரபQபவ%*பாைலவ%?அதி+ 5 
பலக-சாைவ]ெச!அ+ல!தண<8வ%?டைர!கைர!
*Q
ைப பாைன/'ெதா0கவ%டேவ . 
Q
பான!பாைனய%*அQய%+படாம+பா+Q ¼ 
பQயாகஇ/'ேபா!இற/கிஆறியப%*இரச/கரைதஎ!/
ெகாளெவ. 
இUவ%தேமமட/கிமட/கிP*1தடைவகெசய%*இரச/கரமான
!]ைமயாகிவ%. 
வாப%Q/''ணளச8/காைகயா+இதைனேமகடபQ]
ைமெசவதா+அ தத<ய'ணநி*1ேபா'. 
             -  அDேபாகைவதியநவந<த – 4பாகப/க – 91 
 
ரெகாெசயபம !"க 
 
ரபப: 
 திெசதரைதக+வதிலி?ஏJநாந*றாகஅைர!
ப%ற'ேச
கG!/ெகாளH. இ!ேவரபபெம*1ைகயாளா
பகி*ற!. 
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அளH 
 அைரஉC ெதைட (32 மி.கிரா) ய%லி !P*1உC ெதைட 
(195மி.கிரா) வைரஉபேயாகி/கலா. இரஉC ெதைட (130 
மி.கிரா)/'ேமபட/ெகாதா+ேபதியா'. 
!ைணம !, த<ேநாகC: 
 கெவ+லதி+ஏJநாஅ த, 
ெபா!'ணதி*கீg/6ர
ப?டேநாகந<0'. 
ரேச ப$றம !"க 
ெவெள&"ைதல 
ஆதி*னா
பாைளPல 
கவ%g!ைப–இரைடWநிழலிVல8தி/கஷாயமா/கி2பQ   
      எ!/ெகாளH. 
ந+ெலெண – 1பQ 
 மிள', ம-ச, சப%ராண%, ர, ேகாNடவைக/' ¼ 
பலேச8!கா:சிெமJ'பததி+வQதிடH. 
த( ேநா: 
 வாரமிைறதைல/'ேத!/'ள3!வரகண%+வ தமாசித<
. ெவெளJ!/, கம0க+வ%லகிேயா. 
ப%தெமா'*ம0கமேகாதர0கத<. 
ர,க- 
 ஒபல (35 கிரா) ர/க?Qைய, 
ைல
பாலி?
ப!நாஊறைவ!உல8திஎ!/ெகாளH. 
 ெவைள
ைதலதினா+ேமபQ க?Q/' P*1 சாம 
(9மண%) /'/ ெகா!: ரQ ஒ8 ஓ?Q+ ெவQW
 ஐ ! பல 
(175 கிரா) பர
ப%, அத*ேம+ ஊறி வாசலி+ அ
ப%?/ கா+ நாழிைக 
கமல ேபா+ எG/க உ
 உகி ெந
 ப1. அடதி* 
மகிைமயா+ 'ழ ேபால உகி/ ெக?Qயா'. ஓ?Qைன இற/கி/ 
'ள38 த ப%* உைட !
 ர/க?Qைய எ!/ ெகாளH. 
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த(  ேநா: 
 த/க அDபானதி+ க?Qைன உைர!/ ெகா/க ச*ன3ர, 
நாவற?சி, மலவாதச தி ந<0'. 
 
ர,க- 
 சாப%ராண%, க
ர இரைடW சமனா ேச8தைர!, ஒ 
பல (35 கிரா) ர/க?Qய%* ேம+ கவசமி?, உல8தி/ ெகாதி 
எGத ப%ற', கவசைத ந</கி வ%?: சர/ைக எ!/ ெகாளH. 
ர,க- (ேவ
) 
 ெவவ0க, சUவ <ர, ெபா?QV
 சமெவைட க?Q அைர/க: 
ெசந<ர'. இைத/ ெகா அ
ப%ரக தக?Qலி?ட ரதி': /' 
ெகா!, சர/ைக எ/க ேவ/' ைவ!: சீைல ம ெச! 
ழ
டதி+ ைவ! எG! எ!/ ெகாளH. 
 
இரச, கர, .ள/ைக: 
 ைல
பாலி+ P*1 நா ஊGன ர ஐ ! வராகெனைட(21 
கிரா) ைல  ந</கிய ெவைள
 20 வராகெனைட (84 கிரா) 
மிள' 30 வராகெனைட, ெவறிைல 40 வராகெனைட ேச8! ெவறிைல: 
சா1 வ%? ஐ ! சாம (15மண%) அைர!, ைட/கா ேபா+ உ?Q 
நிழலி+ உல8தி ெகாளH. 
அள1 
 ஒ மாதிைர இேவைளயா எJ நா அ தH. 
பதிய 
 உ
, ள3 ந</கH. 
 ஒ ேவைள பபா+ ேச8!/ ெகாளH. எJ நா ெச*ற 
ப%ற' வ1த உ
, !வைர 6?Q பதிைன தா நா ஓம ேத! 
தைல Jகி
 ள3 6?டH. ப%ற' எெணய%? JகH. 
த(  ேநா: 
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 வள3/ கிர தி, இலி0க
1, ெசாறி, கிர தி, ேயான3
1 
'ழி
ப?ட வ%ரண, 'ழி/கிர தி தலியன ேபா. 
 
 
க2சாமிய எ4 ைவதிய ேசகர எ*ற Zலி+ 
பவழ பப  – ப/க 88 
பரசவ ர?சன3  – ப/க 114 
நவH
 திராவக – ப/க 150 
  ேபா*ற ம !கள3+ ர ேசவதாக 'றி
ப%ட
ப?ள!. 
 
சிகி5சா ரன த(ப எ*ற Zலி+ 
1. இரேசா தமாதி Iரண  – ப/க 110 
2. ேகாேராசன மாதிைர  – ப/க 129 
3. கர மாதிைர  – ப/க 138 
4. தால மாதிைர  – ப/க 141 
5. ேசாடச மாதிைர   – ப/க 142 
6. அடைதல   – ப/க 184 
7. ஓனா* ட8 ைதல  – ப/க 185 
8. க தக ைதல   – ப/க 188 
9. மயன ைதல   – ப/க 194  
10. நவ பாஷானத ைதல  – ப/க 197 
11. வ%ரண ச-சீவ% ைதல – ப/க 199 
12. இரச சி ]ர   – ப/க 237 
13. ச
த ரச சி ]ர   – ப/க 242 
14. நவமண% சி ]ர   – ப/க 247 
15. ப-சIத ெமJ'   – ப/க 260 
16. தாமிர ெமJ'   – ப/க 261 
17. வ <ர ெமJ'    – ப/க 265 
18. சிவ
 ெமJ'   – ப/க 270 
19. பட8தாமைர: சிகி?ைச  – ப/க 293 
 16 
20. ேமக ரண/ கள3  – ப/க 304 
   ேபா*ற ம !கள3+ ர ேசவதாக 
'றி
ப%ட
ப?ள!. 
 
யா,ேகா தி வா மலத ள/ய ெப 78 – சன காட 
600 எ*ற Zலி+ 
............. ந<தமா
 ரைத உ
 பX....... 
   
 ெசய ர பய*பவ! பறி 6ற
ப?ள!. 
1. ர: *ன  – பா? 36 
2. ர உ
  – பா? 38 
  ேபா*ற ம !கள3+ ர ேசவதாக 'றி
ப%ட
ப?ள!. 
 
யா,ேகா காட எற 7லி8 
 “ெதாதி?ட வ <ரெமா ர தாD ...... 70 பாட 
சயகாச!/': ெச ]ர   
     எ*ற ம தி+ ர ேச8கிற!. 
 
ைவதிய இரதின  ,க 360 எ*ற Zலி+ – ப/க 164 
 ரச கர பப 
    ெசய ர பய*பவதாக 
'றி
ப%ட
ப?ள!. 
= .வ$. சாபசிவ ப$ைள  5-பாக எற 7லி– ப,க 3821 
 “சாரைத வ%?டா+ ெசயன <G+ைல 
 காரைத வ%?டா+ உ/கினமி+ைல 
 தாரைத வ%?டா+ கள0கி+ைல 
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 வ <ரைத வ%?டா+ மன3கள3+ைல 
 ரைத வ%?டா+ 'Hகள3+ைல” 
 ேமகட வGக Pல ர ' ெசவத8/' பய*ப 
எ*ப! லனாகிற!. 
ைவதிய திற1ேகா8– 7 பாக எ*ற Zலி+ 
 சட மா8தாட ெச ]ர  – ப/க 3 
 வ <ர ெமJ'    – ப/க 4 
 ெதாஷா அமி8த ெமJ'   – ப/க 8 
 ெகா/' ெவைள எைண  – ப/க 4 
  ேபா*ற ம !கள3+ ர ேசவதாக 'றி
ப%ட
ப?ள!. 
 
அகDதிய பEரன 400 எ*ற Zலி+ 
 இரச கர க? – ப/க 36 
 இரச கர ைவ
 – ப/க 23 
 இரச கர 'ள3ைக – ப/க 35 
  ேபா*ற ம !கள3+ ர ேசவதாக 'றி
ப%ட
ப?ள!. 
 
சித ம "வ ெசெப  ைறக எ*ற Zலி+ 
 ர பப   – ப/க 56 
 சிதாதி எெண – ப/க 12 
 நவகிரக எெண – ப/க 34 
 ேமக ராஜ ைதல – ப/க 75 
 ப-சIத ெமJ' – ப/க 124 
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சித ைவதிய திர- எ*ற Zலி+ 
 திGP8தி
 பத0க  – ப/க 192 
 அNட ைபரவ 'ள3ைக  – ப/க 2 
 இலி0க பதி மாதிைர  – ப/க 7 
 ப%ரளயகால திர*  – ப/க 55 
 ஊழி கால*   – ப/க 55 
 வா* ெமJ'   – ப/க 230 
 வாதனாச ைதல  – ப/க 338 
 ெமகவ%ரண/ கள3  – ப/க 358 
   ேபா*ற ம !கள3+ ர ேசவதாக 
'றி
ப%ட
ப?ள!. 
 
ஆமர-சாமித ைவதிய சாரசGகிரக எ*ற Zலி+ 
 கிர தி ேராக படல  – ப/க 385 
 மா த ெசUவா
 கர
பாD/' – ப/க 106 
   ேபா*ற ம !கள3+ ர ேசவதாக 
'றி
ப%ட
ப?ள!.  
 
PIPER BETEL: 
 Since antiquity, Piper betel Linn (betel vine; family Piperaceae) has been an 
important medicinal agent in the various traditional and folk systems of medicine in 
SoutheastAsian countries. The leaves are the most valued plant part and in the past 
were routinely used as a chewing agent to prevent halitosis. The leaves are also 
supposed to harden the gum, conserve the teeth and to prevent indigestion, bronchitis, 
constipation, congestion, coughs and asthma. Innumerable scientificstudies have 
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validatedtheethno medicinalclaims. Betel leavesarean integral component of the betel 
quid that consists of areca nut (Areca catechu Linn.), tobacco (Nicotianatabacum L) 
and slaked lime; a highly abused agent with carcinogenic properties. Regular chewing 
of betel quid is associated mainly with oral cancer and detail studies with individual 
constituents of the quid have shown that both tobacco and areca nut are carcinogenic, 
while slaked lime is shown to promote the process of carcinogenesis.  
 
Table 2: Chemical Constituents of Piper betel[9] 
S.No Compoun
d 
Activity Mode of action 
1 Hydroxy 
-chavicol 
Hyperuremia (antidiabetic), 
immunomodulatory, 
 inhibits platelet aggregation 
A potent COX-1/COX-2-inhibitors, 
ROS scavenger and inhibits platelet 
calcium singnalling, TXB  production 
and aggregation 
2 Allylpyro-
catechol 
Gastric ulcerhealing action, 
anti-inflammatory effect 
Inflammatory response of 
macrophages via inhibition of iNOS, 
COX-2 and IL-12 p40 through down 
regulation of the NFkappaB pathway 
3 Chavi-
betol 
Radioprotective activity Protects photsensitization-mediated 
lipid 
peroxidation of rat liver 
4 Piperbetol Platelet 
Hyperactivity 
Selectively inhibits 
platelet aggregation factor 
 
 
However unlike other constituents of the betel quid, the betel leaves devoid 
carcinogenic effects and on the contrary possesses cancer preventive effects including 
against the carcinogens present in tobacco. Subsequent studies have conclusively 
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shown that the betel leaf and some of its phytochemicals also prevented chemical 
induced cancers in experimental animals [8]. 
 The main chemical constituents of piper betel leaves include Hydroxychavicol 
(HC)/ Hydroxychavicol acetate(HCA), Allylpyrocatechol (APC), Chavibetol (CHV), 
Piperbetol, arecoline, carvacrol, caryophyllene, piperitol, piperbetol, eugenol, 
isoeugenol, allylpyrocatechol, chavicol, safrole, anethole. Chavibetol, 
cadinene.Hydroxychavicol.β-sitosterol,β-sitosterylpalmitate, dotriacontanoic acid, 
tritriacontane, stearic acid, cepharadione, piperine, piperlonguminine. Chavibetol 
acetate, allylpyrocatecholmonoacetate.allyldiacetoxy benzene.estragole, methyl 
eugenol and hydroxycatechol.methylpiperbetol, piperol A and piperol B. cavacrol, 
eugenol acetate, and allylpyrocatecholdiacetate[9]. 
 
ெவறிைல – .ண  
 இன3சிதம!வதி+ெவறிைலபறி6ற
ப?ளக!கைள
காேபா. 
   
  “ஐயஅ10காஅத*சார0ெகாட/கா 
  ைபய:சய%தியேபாைப ேதாQேய! – ெமய%* 
  கQய%*'ணேபா'0காரெவறிைல/'
 
  பQWேதாடமிைத
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PIPER NIGRUM: 
 Black pepper (Piper nigrum) is a flowering vine in the family Piperaceae, 
cultivated for its fruit, which is usually dried and used as a spice. The fruit, known as 
a peppercorn when dried, is approximately 5 millimetres (0.20 in) in diameter, dark 
red when fully mature, and, like alldrupes, contains a single seed. Peppercorns, and 
the powdered pepper derived from grinding them, may be described simply as pepper 
or more precisely as black pepper (cooked and dried unripe fruit), green pepper (dried 
unripe fruit) and white pepper (dried ripe seeds). 
 Black pepper is native to south India, and is extensively cultivated there and 
elsewhere in tropical regions. Currently Vietnam is the world's largest producer and 
exporter of pepper, producing 34% of the world's Piper nigrum crop as of 2008. 
 Dried ground pepper has been used since antiquity for both its flavour and as 
a medicine. Black pepper is the world's most traded spice. It is one of the most 
common spices added to European cuisine and its descendants. The spiciness of black 
pepper is due to the chemical piperine. It is ubiquitous in the industrialized world, 
often paired with table salt. 
 Piper nigrum, commonly is used as a stimulant and carminative and 
prescribed for cholera, dyspepsia, flatulence, diarrhoea and various gastric 
ailments. Several alkaloids and non-alkaloidal constituents have been reported 
from this plant. More than 40 compounds has been isolated from piper nigrum. 
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CURCUMA LONGA(ப மPச) 
 Curcuma longa, a perennial herb and member of the Zingiberaceae 
(ginger) family, grows to a height of three to five feet and is cultivated 
extensively in Asia, India, China, and other countries with a tropical climate. It 
has oblong, pointed leaves and funnel-shaped yellow flowers. The rhizome, the 
portion of the plant used medicinally, is usually boiled, cleaned, and dried, 
yielding a yellow powder. Dried Curcuma longa is the source of the spice 
turmeric, the ingredient that gives curry powder its characteristic yellow colour. 
Turmeric is used extensively in foods for itsflavour and colour, as well as having 
a long tradition of use in the Chinese and siddha systems of medicine, particularly 
as an anti-inflammatory and for the treatment of flatulence, jaundice, menstrual 
difficulties, hematuria, hemorrhage, and colic. Turmeric can also be applied 
topically in poultices to relieve pain and inflammation. Current research has 
focused on turmeric’s antioxidant, hepatoprotective, anti-inflammatory, 
anticarcinogenic, and antimicrobial properties, in addition to its use in 
cardiovascular disease and gastrointestinal disorders[10]. 
ACTIVE CONSTITUENTS: 
 The active constituents of turmeric are the flavonoid curcumin 
(diferuloylmethane) and various volatile oils, including tumerone, atlantone, and 
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zingiberone. Other constituents include sugars, proteins, and resins. The best-
researched active constituent is curcumin, which comprises 0.3-5.4 percent of raw 
turmeric. 
 
 
PHARMACOKINETICS 
 Pharmacokinetic studies in animals have demonstrated that 40-85 percent 
of an oral dose of curcumin passes through the gastrointestinal tract unchanged, 
with most of the absorbed flavonoid being metabolized in the intestinal mucosa 
and liver. 
 Due to its low rate of absorption, curcumin is often formulated with 
bromelain for increased absorption and enhanced anti-inflammatory effect. 
MECHANISMS OF ACTION 
ANTIOXIDANT EFFECTS  
 Water- and fat-soluble extracts of turmeric and its curcumin component 
exhibit strong antioxidant activity, comparable to vitamins C and E. A study of 
ischemia in the feline heart demonstrated that curcuminpretreatment decreased 
ischemia-induced changes in the heart. An in vitro study measuring the effect of 
curcumin on endothelial heme oxygenase-1, an induciblestress protein, was 
conducted utilizing bovine aortic endothelial cells. Incubation (18 hours) with 
curcumin resulted in enhanced cellular resistance to oxidative damage. 
 
HEPATOPROTECTIVE EFFECTS 
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 Turmeric has been found to have a hepatoprotective characteristic similar 
to silymarin. Animal studies have demonstrated turmeric’s hepatoprotective 
effects from a variety of hepatotoxic insults, including carbon tetrachloride 
(CCl),galactosamine, acetaminophen (paracetamol), and Aspergillusaflatoxin. 
Turmeric’s hepatoprotective effect is mainly a result of its antioxidant properties, 
as well as its ability to decrease the formation of proinflammatory cytokines. In 
rats with CCl-induced acute and subacute liver injury, curcumin administration 
significantly decreased liver injury in test animals compared to controls. Turmeric 
extract inhibited fungal aflatoxin production by 90 percent when given to 
ducklingsinfected with Aspergillusparasiticus. Turmeric and curcumin also 
reversed biliary hyperplasia, fatty changes, and necrosis induced by aflatoxin 
production. Sodium curcuminate, a salt of curcumin, also exerts choleretic effects 
by increasing biliary excretion of bile salts, cholesterol, and bilirubin, as well as 
increasing bile solubility, therefore possibly preventing and treating 
cholelithiasis. 
ANTI-INFLAMMATORY EFFECTS 
 The volatile oils and curcumin of Curcuma longa exhibit potent anti-
inflammatory effects. Oral administration of curcumin in instances of acute 
inflammation was found to be as effective as cortisone or phenylbutazone, and 
one-half as effective in cases of chronic inflammation. In rats with Freund’s 
adjuvant-induced arthritis, oral administration of Curcuma longa significantly 
reduced inflammatory swelling compared to controls. In monkeys, curcumin 
inhibited neutrophil aggregation associated with inflammation. C. longa’s 
antiinflammatory properties may be attributed to its ability to inhibit both 
biosynthesis of inflammatory prostaglandins from arachidonic acid, and 
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neutrophil function during inflammatory states. Curcumin may also be applied 
topically to counteract inflammation and irritation associated with inflammatory 
skin conditions and allergies, although care must be used to prevent staining of 
clothing from the yellow pigment. 
 
 
ANTICARCINOGENIC EFFECTS 
 Animal studies involving rats and mice, as well as in vitro studies utilizing 
human cell lines, have demonstrated curcumin’s ability to inhibit carcinogenesis 
at three stages: tumor promotion, angiogenesis, and tumor growth. In two studies 
of colon and prostate cancer, curcumin inhibited cell proliferation and tumor 
growth. Turmeric and curcumin are also capable of suppressing the activity of 
several common mutagens and carcinogens in a variety of cell types in both in 
vitro and in vivo studies. The anticarcinogenic effects of turmeric and curcumin 
are due to direct antioxidant and free-radical scavenging effects, as well as their 
ability to indirectly increase glutathione levels, thereby aiding in hepatic 
detoxification of mutagens and carcinogens, and inhibiting nitrosamine 
formation. 
ANTIMICROBIAL EFFECTS  
 Turmeric extract and the essential oil of Curcuma longa inhibit the growth 
of a variety of bacteria, parasites, and pathogenic fungi. A study of chicks 
infected with the caecal parasite Eimera maxima demonstrated that diets 
supplemented with 1-percent turmeric resulted in a reduction in small intestinal 
lesion scores and improved weight gain. Another animal study, in which guinea 
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pigs were infected with either dermatophytes, pathogenic molds, or yeast, found 
that topically applied turmeric oil inhibiteddermatophytes and pathogenic fungi, 
but neither curcumin nor turmeric oil affected the yeast isolates. Improvements in 
lesions were observed in the dermatophyte- and fungi-infected guinea pigs, and at 
seven days post-turmeric application the lesions disappeared. Curcumin has also 
been found to have moderate activity against Plasmodium falciparum and 
Leishmania major organisms. 
CARDIOVASCULAR EFFECTS 
 Turmeric’s protective effects on the cardiovascular system include 
lowering cholesterol and triglyceride levels, decreasing susceptibility of low 
density lipoprotein (LDL) to lipid peroxidation, and inhibiting platelet 
aggregation. These effects have been noted even with low doses of turmeric. A 
study of 18 atherosclerotic rabbits given low-dose (1.6-3.2 mg/kg body weight 
daily) turmeric extract demonstrated decreased susceptibility of LDL to lipid 
peroxidation, in addition to lower plasma cholesterol and triglyceride levels. The 
higher dose did not decrease lipid peroxidation of LDL, but cholesterol and 
triglyceride level decreases were noted, although to a lesser degree than with the 
lower dose. Turmeric extract’s effect on cholesterol levels may be due to 
decreased cholesterol uptake in the intestines and increased conversion of 
cholesterol to bile acids in the liver. Inhibition of platelet aggregation by C.longa 
constituents is thought to be via potentiation of prostacyclin synthesis and 
inhibition of thromboxane synthesis. 
GASTROINTESTINAL EFFECTS  
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 Constituents of Curcuma longa exert several protective effects on the 
gastrointestinal tract. Sodium curcuminate inhibited intestinal spasm and p-
tolymethylcarbinol, a turmeric component, increased gastrin, secretin, 
bicarbonate, and pancreatic enzyme secretion. Turmeric has also been shown to 
inhibit ulcer formation caused by stress, alcohol, indomethacin, pyloric ligation, 
and reserpine, significantly increasing gastric wall mucus in rats subjected to 
these gastrointestinal insults[10].  
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MERCURY - TOXICOLOGY: 
 
 Mercury is a heavy metal of known toxicity, noted for inducing public health 
disasters.  The clinical impact of smaller mercury exposures remains controversial. It 
exists in several forms: inorganic mercury, which includes metallic mercury and 
mercury vapour (Hg0) and mercurous (Hg2++) or mercuric (Hg++) salts; and organic 
mercury, which includes compounds in which mercury is bonded to a structure 
containing carbon atoms (methyl, ethyl, phenyl, or similar groups). The biological 
behaviour,pharmacokinetics, and clinical significance of the various forms of mercury 
vary with chemical structure. There is some inter conversion in vivo between the 
various forms of mercury. Inhaled elemental mercury vapour, for example, is easily 
absorbed through mucus membranes and the lung and rapidly oxidized to other forms 
(but not so quickly as to prevent considerable deposition of elemental mercury in the 
brain). Methyl mercury is easily absorbed through the gut and deposits in many 
tissues, but does not cross the blood-brain barrier as efficiently as elemental mercury; 
however, on entering the brain it is progressively demethylated to elemental mercury. 
Mercury salts, in contrast, tend to be insoluble, relatively stable, and poorly absorbed. 
Human toxicity varies with the form of mercury, the dose and the rate of exposure. 
The target organ for inhaled mercury vapour is primarily the brain. Mercurous and 
mercuric salts chiefly damage the gut lining and kidney, while methyl mercury is 
widely distributed throughout the body. Toxicity varies with dosage: large acute 
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exposures to elemental mercury vapour induce severe pneumonitis, which in extreme 
cases can be fatal. Low-grade chronic exposure to elemental or other forms of 
mercury induces subtler symptoms and clinical findings, as discussed hereinafter. 
There is considerable controversy about the clinical significance of exposure to the 
various forms of mercury and some disagreement regarding techniques for clinical 
assessment of mercury burden[12]. 
 Mercury exists in nature primarily as elemental mercuryor as a sulfide and is 
found in the earth’s crust at approximately0.5 parts per million. Atmospheric 
exposuresoccur from outgassing from rock or through volcanic activity.Human 
sources of atmospheric mercury include coalburning and mining (mercury and gold in 
particular).Atmospheric elemental mercury settles in water, where it isconverted by 
microorganisms into organic (methyl or ethyl)mercury, which is ingested by smaller 
creatures which areeventually consumed by larger fish. Fish at the top of thefood 
chain (e.g., tuna, swordfish, or shark) may concentrateconsiderable mercury in their 
tissues.Human mercury exposures occur chiefly throughinhalation of elemental 
mercury vapour via occupational ordental amalgam exposure or through ingestion of 
mercurybonded to organic moieties (methyl, dimethyl, or ethylmercury), primarily 
from seafood. Most human metallicmercury exposure comes from mercury vapour 
outgassingfrom amalgam fillings, at a rate of 2 to 28 microgramsper facet surface per 
day, of which about 80% is absorbed,according to the World Health Organization. A 
less common source of mercury vapouris spilled mercury, and there is a report in the 
literatureof Idiopathic Thrombocytopenic Purpura caused byvacuuming spilled 
mercury (thereby producing a majoracute exposure to mercury vapour).Methyl and 
dimethyl mercury (organic mercury) usuallyoriginate from biological sources, chiefly 
fresh or salt waterfish. Over three thousand lakes in the United States havebeen closed 
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to fishing due to mercury contamination and many species of ocean fish are also 
tainted with considerableconcentrations of mercury [13]. 
 
PHARMACOKINETICS OFMERCURY EXPOSURE 
Inorganic Mercury 
 Elemental or Metallic (Hg0) Mercury:Approximately80% of metallic 
mercury vapour outgassed from amalgamsis absorbed through inhalation, compared 
with a bout 7 to 10% absorption of ingested metallic mercury, and about 1% 
absorption of metallic mercury throughskin contact. On entry to the body, mercury 
vapour hasgreat affinity for sulfhydryl groups and bonds to sulfur-containingamino 
acids throughout the body. Mercury vapouris transported to the brain, either dissolved 
in serumor adherent to red cell membranes. Metallic mercury passeseasily through the 
blood brain barrier and through theplacenta, where it lodges in the fetal brain.Metallic 
mercuryis, however, rapidly oxidized to mercuric mercury onentry to the blood 
stream, although not so quickly as toprevent considerable uptake by the central 
nervous system while still in the metallic form.In addition to the brain, metallic 
mercuryis also deposited in the thyroid, breast,myocardium, muscles, adrenals, liver, 
kidneys, skin ,sweat glands , pancreas , enterocytes, lungs, salivary glands, testes, and 
prostate andmay be associated with dysfunction of those organs.Mercuryalso has 
affinity for binding sites on the surface of T cells andfor sulfhydryl groups influencing 
T cell function.Mercury deposits readily in placenta and fetal tissues and isfound in 
breast milk.Metallic mercury is largely excreted as mercuric mercury. The excretory 
half-lives ofmetallic and mercuric mercuryvary widely, depending on the organ of 
deposition and redoxstate, with values ranging from a few days to several months, 
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with some pools (e.g., CNS) having a half-life exceedingseveral years. Hair mercury 
does not correlate withbrain content of metallic mercury. These complexitiesmake 
accurate assessment of body burden challenging[13]. 
Mercurous (Hg2++) Mercury: 
 Mercurous mercury salt in the form of Hg2Cl2 (calomel) is poorly soluble in 
water and poorly absorbed by the intestine, although some portion is thought to 
undergo oxidation to more readily absorbable forms. It is doubtful thatmercurous 
mercury survives in the body, other than as a transitional form between metallic and 
mercuric mercury. Some absorption evidently occurs, however, as calomel is 
occasionally associated with pink disease, or acrodynia. 
 Mercuric (Hg++) Mercury:  
 Historically, mercuric chloride (HgCl2) was used as a preservative and for 
development of photographic film and was ingested accidentally or as a suicide 
measure. It is a component of some skin-lightening creams. Only about 2% of 
ingested mercuric chloride is absorbed initially, although it is believed that its 
corrosive effect on the intestine may increase permeability and, hence, absorption, 
with prolonged exposure. Available data on skin penetration of mercuricmercury are 
insufficient to make quantitative comparison with ingestion or with metallic mercury. 
Like metallic mercury, mercuric mercury in the bloodstream adheres to sulfhydryl 
groups on erythrocytes, metallothionein, or glutathione or is suspended in plasma. 
Mercuric mercury does not cross the blood-brain barrier efficiently, but it does 
accumulate in quantity in the placenta, fetal tissues, and amniotic fluid. Evidence 
exists showing transport of mercuric mercury via one or more amino acid 
transporters,particularly that for cysteine, which may account for accumulation in the 
brain. Much of the body burden of mercuric mercury resides in the proximal 
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convoluted renal tubule bonded to metallothionein. Significant deposition also 
occursperiportally in the liver and lesser amounts in epithelial tissues, choroidal 
plexus, and testes. Excretion of mercuric mercury is largely through urine and stool, 
although significant amounts are shed through sweat, tears, breast milk, and saliva. 
Half -lives appearto be multiphasic, as with metallic mercury, with humanstudies 
suggesting an effective half-life of 42 days for 80%of an oral tracer dose; the other 
20% did not appear tohave a measureable rate of excretion. This may 
reflectdemethylation to metallic mercury in the brain and otherorgans or mechanisms 
yet to be determined. 
 
Organic Mercury Compounds: 
 Most available data onorganic mercury compounds refer to methyl mercury, 
whichis a major source of human mercury exposure, is found naturallyin fish, and is 
relatively stable. Ethyl mercury behavesin a similar fashion to methyl mercury at the 
cellular level,but with an excretory half-life about one third as long.Methyl mercury 
vapour is absorbed with similar (80%)efficiency as metallic mercury vapour. 
Intestinal absorptionof methyl mercury from fish is also fairly efficient, asis 
absorption through the skin. On entry to the bloodstream,methyl mercury adheres to 
sulfhydryl groups, particularlyto those in cysteine. Methyl mercury is 
depositedthroughout the body, with equilibrium between blood andbody occurring 
approximately four days after exposure.Distribution to peripheral tissues seems to 
occur throughone or more transporters, especially the cysteine transporter,probably 
adherent to the sulfhydryl group in cysteine.Concentration of methyl mercury occurs 
in the brain,liver, kidneys, placenta, and fetus, especially in the fetalbrain, as well as 
in peripheral nerves and bone marrow.Deposited methyl mercury slowly undergoes 
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demethylationto inorganic mercury.The excretory half-life of methyl mercury in man 
is about70 days, with approximately 90% being excreted in stool.Some degree of 
enterohepatic circulation apparently occurs.Perhaps 20% of methyl mercury is 
excreted in breast milk,with the actual amount varying with severity of exposure.Hair 
mercury reflects blood methyl mercury at the time ofincorporation, but not elemental 
mercury, and hence isnot a good index of total body burden, given the short half-life 
of methyl mercury in blood.Dimethyl mercury is also efficiently absorbed throughthe 
skin, and there is a reported death of a scientist causedby minimal skin contact[13]. 
Toxicity 
Inorganic Mercury 
Metallic Mercury Vapour: 
 Mercury in all forms poisonscellular function by altering the tertiary and 
quaternarystructure of proteins and by binding with sulfhydryl andselenohydryl 
groups. Consequently, mercury can potentiallyimpair function of any organ, or any 
subcellular structure.The chief target organ ofmercury vapour is the brain, but 
peripheralnerve function, renal function, immune function,endocrine andmuscle 
function, and several types of dermatitishave been described.With massive acute 
exposure to mercury vapour, erosivebronchitis and bronchiolitis potentially leading to 
respiratoryfailure may be accompanied by CNS symptoms such astremor or erethism. 
 Chronic exposure to clinically significant doses of mercuryvapour usually 
produces neurological dysfunction. Atlow-level exposures, nonspecific symptoms like 
weakness,fatigue, anorexia, weight loss, and gastrointestinal disturbancehave been 
described. Higher exposure levels areassociated with mercurial tremor: fine muscle 
fasciculationspunctuated every few minutes by coarse shaking. Erethismmay also be 
observed: severe behaviour and personality changes,emotional excitability, loss of 
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memory, insomnia, depression,fatigue, and in severe cases delirium and hallucination. 
Gingivitis and copious salivation have beendescribed.These symptoms may regress 
with cessation of exposure,but in many cases do not. Persistent neurological 
symptomsare common. 
Mercurous Mercury:  
 Calomel (Hg2Cl2) is still used insome regions of the world as a laxative. 
Although poorly absorbed,some is converted to mercuric mercury, which is 
absorbed,and induces toxicity as expected with mercuric mercury. 
MercuricMercury:  
 Acute poisoning with mercuric salts(typically HgCl2) generally targets the 
gastrointestinal tractand the kidneys. Extensive precipitation of enterocyte 
proteinsoccurs, with abdominal pain, vomiting, and bloodydiarrhoea with potential 
necrosis of the gut mucosa. Thismay produce death either from peritonitis or from 
septic orhypovolemic shock. Surviving patients commonly developrenal tubular 
necrosis with anuria.Chronic poisoning with mercury salts is rare, usually 
alsoinvolving concomitant occupational exposure to mercuryvapour. Kidney toxicity 
involves either renal tubular necrosisor autoimmune glomerulonephritis, or both. 
Immunedysfunctions include hypersensitivity reactions to mercuryexposure, 
including asthma and dermatitis, various typesof autoimmunity, and suppression of 
natural killercells and disruption of various other lymphocyte subpopulations.Brain 
dysfunction is less evident than with other formsof mercury. Thyroid dysfunction 
seems associated with inhibitionof the 5_ deiodonases, with decreased free T3 and 
increasedreverse T3. Accumulation in the testicles appearsto inhibit spermatogenesis. 
Atrophy and capillary damagehave been described in thigh muscle. 
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OrganicMercury: 
 Methylmercury reacts with sulfhydrylgroups throughout the body, therefore 
potentially interferingwith the function of any cellular or subcellular structure. 
Mercury is believed to interfere with DNA transcription andprotein synthesis, 
including protein synthesis in thedeveloping brain, with destruction of endoplasmic 
reticulumand disappearance of ribosomes. Evidence suggests disruptionof numerous 
subcellular elements in the central nervoussystem and other organs and in 
mitochondria; adverseeffects have also been described on heme synthesis,cell 
membrane integrity in many locations, free radicalgeneration, neurotransmitter 
disruption, andstimulation of neural excitoxins, resulting in damage tomany parts of 
the brain and peripheral nervous system.Methyl mercury has been associated with 
reduction inNatural Killer cell activity, as well as an imbalance Th2: Th1 ratios 
favouring autoimmunity. 
 Mercury is also possibly associated with disruption of DNArepair. The affinity 
of mercury for sulfhydryl groupsof the mitochondrial oxidative phosphorylation 
complexassociated with destruction of mitochondrial membranesmay contribute to 
chronic fatigue syndrome.  
 
5. Clinical Presentation 
Inorganic 
Elemental (Metallic) Mercury:  
 Acute exposure to alarge quantity ofmercury vapour induces pneumonitis, as 
discussedpreviously. Symptoms of low-grade chronic exposureare more subtle and 
nonspecific: weakness, fatigue, anorexia,weight loss, and gastrointestinal distress, 
sometimes referredto as micromercurialism. At higher exposures, themercurial fine 
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tremor punctuated by coarse shaking occurs;erethism, gingivitis, and excessive 
salivation have also beendescribed, as has immune dysfunction.Objective findings 
include altered evoked potentialsand decreased peripheral nerve conduction 
velocity.Objective measures of short-term memory may be inverselycorrelated with 
urinary mercury in chloralkali workers.Reduced colour vision and visual acuity have 
also been observed. Changes in coordination, tremor, mental concentrationcapacity, 
facial expression, and emotional stateare also described, as are polyarthritis, various 
forms ofdermatitis, and a syndrome mimicking pheochromocytoma.Subtler clinical 
findings among dentists have been documented,including delayed reaction time, poor 
fine motorcontrol, and deficits in mental concentration, vocabulary,task switching, 
and the One Hole test, as well as mood lability,all correlating with urinary mercury 
excretion. Evidencealso links elemental mercury to depression, excessiveanger, and 
anxiety, as well as acute myocardial infarction,lipid peroxidation, and carotid 
atherosclerosis, in Finland; the Finnish experience may possibly be explainedby 
dietary selenium deficiency, since selenium antagonizesmercury toxicity. Other 
investigators, however, havedescribed associations between mercury and 
hypertension,lipid peroxidation, ischemic heart disease, and stroke[13]. 
 
Mercuric Salts: 
 Ingestion of mercuric chloride producesextensive precipitation of intestinal 
mucosal proteins,mucosal necrosis, generalized abdominal pain, bloody diarrhea,and 
shock. If the patient survives, acute renal failuremay follow. 
 
Organic Mercury: 
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 Methyl mercury and ethyl mercuryproduce similar signs and symptoms. Most 
published datarefer to methyl mercury. Symptoms relate more to magnitudeof methyl 
mercury retention than to the rate of deposition.Acute exposures tend to have a 
latency period of one ormore weeks; once acquired, toxic doses are cleared slowly, 
ifat all.Massive prenatal poisoning may induce a form of cerebralpalsy. Lesser 
prenatal doses have been associated withneuro-developmental delays and cognitive 
deficits.Postnatal exposures generate a range of symptoms rangingfrom paresthesias, 
with lesser exposures, to ataxia, visual,auditory, and extrapyramidal impairments with 
moderateexposures and clonic seizures in more severe exposures. Objective physical 
findings are similar to those seen withelemental mercury exposure. 
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AIM AND OBJECTIVES: 
AIM: 
 To purify calomel(ர) and prepare Poora Parpam using traditional siddha 
methods with detailed study on acute and long term toxicity of “POORA PARPAM” 
in animal model (Wister albino rats) 
OBJECTIVE: 
1. Purification of POORAM using siddha literature 
2. Preparation of POORA PARPAM using siddha literature 
3. Chemical analysis of POORA PARPAM 
4. Toxicity study on “POORA PARPAM” using animal models 
a. Acute toxicity 
b. Chronic toxicity 
 
 
  
 41 
 
 
 
 
 
MATERIALS 
AND 
METHODS 
 42 
MATERIALS AND METHODS: 
MATERIALS REQUIRED: 
PURIFICATION: 
1. Calomel (திெசயாதர) 
2. Piper betel (கமா1ெவறிைல) 
3. Piper nigrum(ந+லமிள') 
4. !லாஎ திர/கவ% 
DRUG PREPARATION: 
1. Calomel(திெசதர) 
2. Piper betel(கமா1ெவறிைல) 
3. Boiled rice(ேவகைவதஅGசி) 
4. Curcuma aromatic(ம-ச) 
5. Crab fat(ந ெகாJ
) 
TOXICOLOGICAL STUDY: 
Animals - Wistar albino rats (200 ± 25 g) bred in the animal house of GSMC, 
palayamkottai, were used. The animals were housed in wire-bottomed cages under a 
uniform condition of temperature and humidity and fed with normal food and tap 
water.  
Chemical analysis: 
1. Ammonium oxalate 
2. Barium chloride 
3. Silver nitrate 
4. Con. Hydro chloric acid 
5. Iodine solution 
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6. Glacial acetic acid 
7. Potassium ferro cyanide 
8. Con. Nitric acid 
9. Ammonium thiocyanate 
10. Ammonium molybdate 
11. Esbatch’s reagent 
12. Ferric chloride 
13. Potassium permanganate 
14. Ninhydrin 
15. Potassium ferrocyanide 
METHODS: 
PURIFICATION: 
 8.75g of leaves of piper betel leaves and 8.75g of black pepper are taken and 
grinded using water and is made in to a paste. This is then dissolved in 1.3L of water. 
This solution is kept in the lower vessel of Thulaaenthiram (!லாஎ திர/கவ%).  
 
Figure 1: "லாஎ!திர,க வ$ 
 
 
 
 
 
 
Po
or
 
 44 
A single piece of pooram weighing around 35g is then tied in a thread and is allowed 
to hang inside the vessel containing solution. The whole setup is the heated from 
below till the amount of solution is reduced to 1/4th of the total amount. Then the 
pooram is washed and stored in a container. 
DRUG PREPARATION: 
 A single piece of purified pooram is taken and is completely covered with the 
mixture of boiled rice and turmeric. This is then kept in a clay vessel and is heated 
from below. 
  
Figure 2: Drug Preparation 1 
Heat should be applied till the outer covering gets blackish colour. Same procedure is 
repeated 10 times.Then the processed piece of pooram is heated in a clay pot and crab 
fat is applied on the pooram piece, so that the piece absorbs the poured crab fat.This 
process should be done continuously for 24 hours. This is then cooled, made in to fine 
powder and is stored.   
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Figure 3: Poora Parpam Preparation 
TOXICOLOGY STUDY: 
SELECTION OF ANIMAL SPECIES: 
         Usually animal experiments are conducted on mice,albino rats,rabbit and 
dog.Young and immature animals should be selected for the study. In case of albino 
rats,it should be 180-200gm weight and 12 weeks growth. 
PREPARATION OF ANIMALS: 
            Animals should be properly caged and should be fed properly with adequate 
diet. Allowthe animals to be in the cage for 5 days before drug administration,in order 
to make them accustomed to the new environment.The temperature maintained in the 
animal house should be 12 hours dark and the remaining 12 hours full of light.Only 
healthy animals should be selected for the study. 
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PREPARATION OF THE DRUG: 
             The drug used for animal study should be free from microbes.Highly irritant 
and highly toxic drugs should not be given to the animals.The drug must dissolve in 
any one of the suspending agents such as water,milk,honey, castor oil etc. 
PREPARATION OF DOSES: 
1. While doing animal study the dose of the drug given is determined on the 
basis of body weight of the animal. 
2. In case of mice and albino rats, the dose of the drug must be 1 ml/ 100gm. 
body weight. 
3. When water soluble drugs are given, it must be 2 ml/100 gm. body weight. 
4. The adjuvant (அDபான) used should be free from toxic properties. 
ADMINISTRATION OF DRUG: 
             During drug administration care should be taken that the drug does not enter 
into the respiratory passage. Before drug administration,the animal has to be fasted.In 
case of albino rats the fasting period is 12hours.The weight of the animal has to be 
noted before drug administration. Then the drug is administered to the animal. Later 
the albino rats are fed with proper diet 1-2 hours and 3-4hours respectively after drug 
administration. 
NUMBER OF ANIMALS AND DOSE LEVELS: 
                The dose of the drug given to the animal depends upon. 
1. Body weight of the animal 
2. Metabolic rate of the animal 
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                  While conducting acute toxicity study the number of animals in each 
group should be 5+5.Animals of both sex should be used.In case of chronic toxicity 
study the animals are divided into 4 groups,each group consisting of 20+20 animals. 
OBSERVATION: 
                   In acute toxicity study,the animals are carefully observed during the first 
30 minutes and then observed for 24 hours.During that period,the animal may show 
changes in the skin, eye,mucous membrane,blood circulation,respiratory movements 
and the neurological problems may arise. 
                    In case of sub-acute toxicity study the animals have to be observed for 90 
days or sometimes up to 1 year .Some researchers conduct the chronic toxicity study 
for the whole lifetime of the animal. 
BODY WEIGHT OF THE ANIMAL: 
                    The weight of the animal must be taken four times during the course of 
study. 
i. First before drug administration. 
ii. One Week after drug administration. 
iii. Two weeks after drug administration. 
iv. Before sacrificing the animal.         
DATA AND REPORT:  
                         At the end of the animal study,the following data must be given. 
1.Number of animals selected for the study. 
2.Number of animals died due to the toxicity of the drug given. 
3.Number of animals sacrificed at the end of animal study. 
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4.Changes in animal behaviour due to acute and chronic toxicity. 
5.Histo-pathological changes in the internal organs such as liver, 
kidney and heart.  
CHRONIC TOXICITY STUDY 
1. This experiment has to be carried out 90 days to one year or 
one year to five years or entire life span of the animal. 
2. Observe the animal daily and record the findings observe for 
cumulative effect of toxicity. 
 
CHEMICAL ANALYSIS: 
PREPARATION OF EXTRACT: 
 100mgs of the drug is weighed accurately and placed in a clean beaker and 
few drops of Con. Hcl is added and allowed to evapourate. Then it is allowed to cool 
and few drops of Con. Nitric acid is added. It is then allowed to cool and 20ml of 
distilled water is added so that it gets dissolved in it. This is then transferred to 100ml 
volumetric flask and is made up to 100ml with distilled water. This is then mixed, 
filtered and is taken for analysis. 
TEST FOR CALCIUM: 
 2ml of the extract is taken in a clean test tube and 2ml of 4% ammonium 
oxalate solution is added to it. Appearance of white precipitate indicates the presence 
of calcium. 
TEST FOR SULPHATE: 
 2ml of the extract is added to 5% barium chloride solution. Appearance of 
white precipitate indicates the presence of sulphate. 
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TEST FOR CHLORIDE: 
 Extract is treated with silver nitrate solution. Appearance of white precipitate 
indicates the presence of chloride. 
TEST FOR CARBONATE: 
 The substance is treated with concentrated hydrochloric acid. Appearance of 
brisk effervescence indicates the presence of sulphate. 
TEST FOR STARCH: 
 The extract is added with weak iodine solution. Formation of blue colour 
indicates the presence of starch. 
TEST FOR IRON: 
 The extract is acidified with glacial acetic acid and potassium ferrocyanate is 
added. Formation of blood red colour indicates the presence of ferrous iron. 
TEST FOR PHOSPHATE: 
 The extract is treated with ammonium molybdate and concentrated nitric acid. 
Appearance of yellow precipitate indicates the presence of phosphate. 
TEST FOR ALBUMIN: 
 Extract is treated with Esbatch’s reagent. Formation yellow precipitate 
indicates the presence of albumin. 
TEST FOR TANNIC ACID: 
 The extract is treated with ferric chloride. Appearance of black precipitate 
indicates the presence of tannic acid. 
TEST FOR UNSATURATION: 
 Potassium permanganate is added to the extract. Decolourisation of the 
solution indicates the presence of unsaturated fatty acids 
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TEST FOR REDUCING SUGAR: 
 5ml of benedict’s solution is taken in a test tube and allowed to boil for 2 
minutes. Then 8-10 drops of extract is added to it and is boiled for 2 minutes. 
Significant colour change indicates the presence of reducing sugar. 
TEST FOR AMINO ACID: 
 One or two drops of the extract is placed on a filter paper and dried. After 
drying 1% Ninhydrin is sprayed over it and dried. Formation of violet colour indicates 
the presence of amino acid. 
TEST FOR ZINC: 
 The extract is treated with potassium ferro cyanide. Appearance of white 
precipitate indicates the presence of zinc. 
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RESULTS: 
PURIFICATION: 
Weight of raw pooram – 200g 
Weight of piper betel – 54g 
Weight of piper nigrum – 54g 
Amount of water – 6L 
Weight of pooram after purification – 192g 
 The above data’s showed that their is loss of total of 8g from 200g of pooram 
taken for purification. Totally there is loss of 4% of raw drug after purification. 
POORA PARPAM – PREPARATION: 
 
Weigth of  purified Pooram – 192g 
Amount of boiled rice – 250g 
Amount of turmeric powder – 100g 
Total No. of Crabs – 200 (6.5 kgs) 
Weight of Poora parpam before grinding – 190g 
Weight of Poora parpam after grinding – 185g 
 The above data’s indicate that 185g of pooraparpam is prepared from 192g of 
purified pooram with 3.2% weight loss. 
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CHEMICAL ANALYSIS: 
Table 3: Chemical Analysis of Poora Parpam 
S.No Substance Result 
1 Calcium + 
2 Sulphate + 
3 Chloride + 
4 Carbonate - 
5 Starch - 
6 Ferric iron - 
7 Ferrous iron + 
8 Phosphate - 
9 Albumin - 
10 Tannic acid - 
11 Unsaturated compounds + 
12 Reducing sugar - 
13 Amino acid - 
14 Zinc - 
 
 Data’s in the above table indicates that small amount of unsaturated 
compounds, ferrous iron, chloride, sulphate and calcium are present in Poora Parpam.  
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TEST FOR METALS: 
 
Table 4: Test for Metals in Poora Parpam 
S.No Metals Amount 
1 As193.696 (Arsenic) BDL 
2 Cd 226.502  (Cadmium) BDL 
3 Cu 324.754 (Copper) BDL 
4 Hg253.652 (Mercury) 3.421mg/L 
5 Pb 230.204  (Lead) BDL 
 
BDL = Below detection limit 
The above data show that mercury is present in large quantity in the drug. But all 
other metals such as lead, cadmium, copper, and arsenic are below detection limits. 
 
Total amount of poora parpam in 1000ml of sample = 1000mg 
That implies 1000mg of Poora Parpam has 3.421mg of mercury 
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FOURIER TRANSFORMINFRARED SPECTROMETRY REPORT: 
  
 
 
 
Figure 4: FTISR Raw Pooram 
 
 
Figure 5: FTISR Purified Pooram 
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Figure 6: FTISR Poora Parpam 
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TOXICITY STUDY: 
The toxicity evaluation of PooraParpam is carried in two phases. 
 Phase I - Acute toxicity study. 
 Phase II - Chronic toxicity study. 
ACUTE TOXICITY STUDY 
Animals 
 Wister albino rats bred in the animal house attached to the pharmacology 
Department, Government Siddha Medical College, Palayamkottai were used. 
Sex 
 Animals of both sexes were used. 
Weight 
 Animals weighing between 80-120 gm. were selected. 
Food and water 
 The animals were maintained with standard animal feed and water ad-libitum.  
Number of Animals 
 24 Albino rats divided into 6 groups each group consisting of 4 rats. 
Dose Levels 
 The following dose levels were fixed by presuming range of least toxic to high 
toxic doses. 
I Group - Control 
II Group - 40 mg/100 gm body weight of the animal. 
III Group - 80 mg/100 gm body weight of the animal. 
IV Group - 160 mg/100 gm body weight of the animal. 
V Group - 320 mg/100 gm body weight of the animal. 
VI Group - 640 mg/100 gm body weight of the animal. 
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Route of administration 
 The drug was administered orally. 
Drug preparation 
 The drug was weighted and taken and suspended in castor oil. The mixture 
was ground well before the administration.  The preparation was done in such a way 
that 1ml of suspension contains dose ranging from 40mg to 640 mg of Poora Parpam 
which is given to the respective groups, as classified above in the doses level.  The 
drug was administrated in morning and observed. 
Observation 
 The following details were recorded 
CENTRAL EFFECTS: 
I. Stimulation 
1. Hyperactivity 
2. Pyloerection 
3. Twitching 
4. Rigidity 
5. Irritability 
6. Jumping 
7. Clonic convulsions 
8. Tonic convulsions 
II. Depression 
1. Ptosis 
2. Sedation 
3. Sleep 
4. Loss of traction 
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5. Loss of pinna reflex 
6. Ataxia 
7. Loss of muscle tone 
8. Analgesia 
III. Autonomic Effects 
1. Straub tail 
2. Laboured respiration 
3. Cyanosis 
4. Blanching 
5. Reddening 
6. Abnormal secretions 
 At the end of 24 hours the number of animals live or dead in each group was 
noted and the approximate LD 50 was determined.  The animals were 
morphologically examined for any toxic symptoms. 
CHRONIC TOXICITY STUDY: 
Animals 
 Wister albino rats bred in the animal house attached to the Pharmacology 
Department, Government Siddha Medical College, Palayamkottai were used. 
Sex 
 Animals of both sexes were used. 
Weight 
 Animals weighing between 80-120 gm. are selected. 
Food and water 
 The animals were maintained with standard animal feed and water ad-libitum. 
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Number of Animals 
 12 Albino rats are divided into 3 groups each group consisting of 4 rats. 
Dose Levels 
 Two doses were selected from the acute toxicity study.  These doses did not 
have any acute toxicity effect and presumed to be safe for long term administration in 
animals. 
I Group  - Control 
II Grou p  - 40mg / 100 gm. body weight of the animal. 
III Group  - 80mg / 100 gm body weight of the animal. 
Route of administration 
 The drug was administered orally for about 3 months. 
Drug preparation 
 The drug was weighted and taken and suspended in Ghee, the mixture was 
ground well before the administration.  The preparation was done in such a way that 1 
ml of suspension contains dose ranging from 40 mg/ml and 80mg/ml of Poora Parpam 
for the groups taken.  The prepared drug was administrated once a day (morning) for 
90 days. 
Observation 
 The following details were recorded before and after the drug administration. 
Body weight of the animal 
Haematological investigation 
1. W.B.C Total count 
2. W.B.C Differential count 
3. Haemoglobin 
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Every month and at the end of the experiment, the above parameters were recorded 
and the resultsare tabulated. 
 One animal from each group, were sacrificed at the end of the experiment and 
were dissected.  The visceral organs like Liver, Kidney and Heart were removed from 
each animal and were preserved in 40% formalin solution send for Histo-pathological 
studies. 
Histo-pathological procedure: 
 The sections were stained with haemotoxillin and eosin and the histo-
pathological report was given by Dr.Swaminathan, Professor Pathology Department, 
Tirunelveli Medical College. 
 The tabular column shown in tested parameters and changes in histo-
pathological specimens were also documented. 
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Table 5: Acute Toxicity Study of Poora Parpam  at control 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead 
after 24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
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- 
 
--Negative           + Positive 
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Table 6: Acute toxicity study at a dose of 40mg/100 gm body weight 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead 
after 24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
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- 
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- 
 
  --Negative           + Positive 
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Table 7: Acute Toxicity Study at a dose of 80mg/100 gm body weight 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead after 
24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
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- 
 
- 
 
  --Negative           + Positive 
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Table 8: Acute Toxicity Study at a dose of 160mg/100 gm body weight 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead after 
24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
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- 
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- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
 
- 
 
  --Negative           + Positive 
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Table 9: Acute Toxicity Study at a dose of 320mg/100 gm body weight 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead after 
24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
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- 
- 
- 
- 
- 
- 
- 
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- 
- 
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- 
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- 
- 
- 
 
- 
 
  --Negative           + Positive 
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Table 10: Acute Toxicity Study at a dose of  640mg/100 gm body weight 
Observation At 1 hr At 2 hrs At 4 hrs At 24 hrs 
I.Stimulation: 
Hyperactivity 
Pyloerection 
Twitching 
Rigidity 
Irritability 
Jumping 
Clonic convulsions 
Tonic convulsions 
II.Depression: 
Ptosis 
Sedation 
Sleep 
Loss of traction 
Loss of pinna reflex 
Ataxia 
Loss of muscle tone 
Analgesia 
III. Autonomic effect: 
Straub tail 
Laboured respiration 
Cyanosis 
Blanching 
Reddening 
Abnormal Secretions 
IV.Number of dead after 
24 hrs: 
 
- 
- 
- 
- 
- 
- 
- 
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- 
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  --Negative           + Positive 
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Acute Toxicity Study 
 The said parameters in acute toxicity study were observed on six groups 
(Group I, II, III, IV, V, VI). Group II, III, IV, V, VI were administrated with drugs 
such as 40mg, 80mg, 160mg, 320mg, 640mg /100 gm body weight of the animal 
respectively. 
 The results were tabulated in the table 1 to 6.  From the table 2 to 6 it being 
found that the drug Poora Parpam did not produce any mortality even upto 320mg 
/100 gm body weight of the animal. 
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S.No Blood 
At O’ day 
(Mean) 
At 30th day 
(Mean) 
At 90th day 
(Mean) 
1 WBC Total count 8900/cumm 9100/cumm 9200/cumm 
2 
Differential Count 
Neutrophil 28% 26% 24% 
Eosionophil - - - 
Basophil - - - 
Lymphocyte 72% 74% 76% 
Monocyte - - - 
3. Haemoglobin % 66 68 70 
4. Body Weight 
100 
g
m
102 
g
m
104 
g
m
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                                       TABLE NO:8 
Changes in the parameters of weight and Hematological indices 
Group II animals: 40mg / 100mg body weight of the animal 
S.No Blood 
At O’ day 
(Mean) 
At 30th day 
(Mean) 
At 90th day 
(Mean) 
1 WBC Total count 9500/cumm 9700/cumm 9800/cumm 
2 
Differential Count 
Neutrophil 32% 28% 24% 
Eosionophil - - - 
Basophil - - - 
Lymphocyte 68% 72% 76% 
Monocyte - - - 
3. Haemoglobin % 68 70 72 
4. Body Weight 
100 
g
m
105 
g
m
110 
g
m
   
 71 
                                             TABLE NO:9 
Changes in the parameters of weight and Hematological indices 
Group III animals: 80mg / 100mg body weight of the animal 
S.No Blood 
At O’ day 
(Mean) 
At 30th day 
(Mean) 
At 90th day 
(Mean) 
1 WBC Total count 9200/cumm 9400/cumm 9600/cumm 
2 
Differential Count 
Neutrophil 30% 26% 20% 
Eosionophil - 2 2 
Basophil - - - 
Lymphocyte 70% 72% 78% 
Monocyte - - - 
3. Haemoglobin % 66 68 70 
4. Body Weight 
100 
g
m
110 
g
m
120 
g
m
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Table 10 
                                                Acute Toxicity Study Analysis 
Group Dose in mg/100gm body  
weight of animal 
No of rats No of rats  
died 
II 40 4 - 
III 80 4 - 
IV 160 4 - 
V 320 4 - 
VI 640 4 - 
 
 Since there is no mortality of the animal in Acute toxicity study, lethal 
dose of drug need not be calculated. 
  
  
 73 
    Table 11 
                                        Chronic Toxicity Study Analysis 
Group Dose in mg/100gm 
body  
weight of animal 
No of rats Days No of rats  
died 
I 40 4 0 - 
30 - 
90 - 
II 80 4 0 - 
30 - 
90 - 
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 Median Lethal Dose (LD 50): 
 It is the dose which kills half the population of the animal tested. 
Since there is no mortality of the animal in chronic toxicity study, lethal dose 
of drug need not be calculated. 
 In case of Chronic Toxicity Study, with the help of physiological 
parameter such as haematological & Histopathological studies the drug 
reaction within the animal can be assessed and being tabulated 
respectively. 
 
  
 HISTO-PHATHOLOGY 
HISTOPATHOLOGY OF LIVER OF 
 
 
 
STUDY 
RAT: 
  
 
 
Low Dose Exposure
studied shows liver tissue with 
dilated central vein with 
congested sinusoids.
High D
studied shows liver tissue with 
dilated central vein with 
congested sinusoids.
Control
normal liver tissue
75 
: Section 
 
ose Exposure: Section 
 
: Section studied shows 
 
 
 HISTO-PHATHOLOGY OF KIDNEY
 
 
 
 
 
 OF RAT: 
  
 
 
 
Low Dose Exposure
studied shows normal glomeruli 
with focal cloudy 
the tubules
High Dose Exposure
studied shows normal 
glomeruli with focal cloudy 
swelling of the tubules
Control
normal kidney tissue
76 
: Section 
swelling of 
 
: Section 
 
: Section studied shows 
 
 
 HISTO-PHATHOLOGY OF HEART 
 
 
 
 
 
OF RAT: 
  
 
 
 
Low Dose Exposure
studied shows normal 
of myocardial fibers.
High Dose Exposure
studied shows normal bundles 
of myocardial fibers.
 
Control
normal heart tissue
77 
: Section 
bundles 
 
: Section 
 
: Section studied shows 
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DISCUSSION: 
 According to the research done so far, the amount of mercury in Poora Parpam 
is around 3.42µg/g. The therapeutic dose of Poora Parpam is usually 65mg/dose with 
consumption of three times a day. That shows if a person consumes Poora Parpam 
under these regulations, total intake in a week will be 1.2mg. Which implies total 
intake of mercury in a week will be 4.1µg. In 2004 the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) established a tolerable intake of 1.6 µg/kg 
bodyweight per week for methylmercury in order to protect the developing fetus from 
neurotoxic effects.For adults, up to about twice the tolerable intake per week would 
not pose any risk of neurotoxicity.So amount of mercury present in Poora Parpam is 
slightly (0.9µg)higher than permissible limits of mercury for a week in adults. But 
ingestion of 10times the dosage of drug doesn’t showed any notable toxic symptoms 
in animals. This contrary result in animal study may be due to the fact that the drug is 
administered along with castor oil as adjuvant, which may play an important role in 
reducing its toxic properties. Moreover, the permissible limits regulations by WHO 
applies mainly to long term exposure to mercury for months. But usually the drug is 
given only for a week.  
 In case of humans, some factors such as food habits may also play an 
important role in determining the toxicity of mercury-containing drugs. Because most 
of the toxicity work done by WHO is on western population, which follows very 
different food habits compared with a normal Indian population. For example, intake 
of common food ingredients such as sesame oil, turmeric, tamarind, garlic, and 
asafoetida may play an important role in prevention of toxic effects of mercury. This 
becomes more evident from the south Indian population which consumes sea food in 
large amount.  A recent research suggest that average mercury concentration obtained 
in muscle of deep sea fishes that is regularly consumed by south-east Indian 
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population was 1.6 mg/kg dry weight (0.352 mg/kg wet weight), which is higher than 
the prescribed limits (0.3 mg/kg wet weight). But there are no notable toxic effects 
due to mercury such as Alzeimer’s disease, autism in south indian population when 
compared with the western population. This may be due to the protective mechanism 
of indian food ingredients. 
 In histo-pathology studies, traces of mercury are present in liver and kidney. 
But this may be reversible, as it didn’t produce any significant toxic symptom in 
animals. Usually metallothionins – a cysteine rich protein plays an important role in 
protection against mercury toxicity in tissues by binding with mercury. But excretion 
of mercury from kidney may take a long time as mercury gets deposited in glomerular 
tissues due to effective tubular reabsorption. However, presence of metallothionins 
protects liver and kidney from effective damage though it won’t play any effective 
role in removal of mercury from our body. Various cell culture studies have shown 
that turmeric, garlic and tamarind plays an important role in increasing metallothionin 
production in cultured cells. These data’s further supports the proposed mechanism of 
protective role of food diets in Indian population against mercury.  
Another unexplored facet, which could affect the efficacy and toxicity of these 
drugs, are drug-drug interaction that occurs when they are given in combination with 
other herbal preparations. The fact that mercury sulfide is insoluble and does not get 
absorbed through blood circulation eliminates its chances of providing therapeutic 
benefits, since it may not react at all with the cell receptors. However, incorporation 
of herbal ingredients in these preparations may alter the cell uptake, distribution, and 
elimination profile as well as the therapeutic properties. So a detailed study on all 
these factors is necessary. 
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Summary: 
 This study aims at evaluating the toxicity profile of Poora Parpam, 
commonly used siddha drug in treatment of various metabolic disorders. Raw Pooram 
is first purified using piper betel and piper longum, and Poora parpam is then prepared 
using unique method mentioned in Aruvai maruthuvam. Basic chemical analysis was 
performed to study the presence of various elements present in the drug along with 
detailed toxicology study using animal models.  According to the chemical analysis 
done, the amount of mercury in Poora Parpam is around 3.42µg/g. The therapeutic 
dose of Poora Parpam is usually 65mg/dose with consumption of three times a day. 
That shows if a person consumes Poora Parpam under these regulations, total intake 
in a week will be 1.2mg. Which implies total intake of mercury in a week will be 
4.1µg. But this  amount of mercury present in Poora Parpam is slightly (0.9µg) higher 
than permissible limits of mercury for a week in adults declared by the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) In 2004.  
 In contrary to the chemical analysis, administration of 10 times the 
therapeutic dosage in acute toxicity study doesn’t show any notable toxic symptoms 
in animals. This may be due to the fact that the drug is administered along with castor 
oil as adjuvant, which may play an important role in reducing its toxic properties. 
Moreover, the permissible limits regulations by WHO applies mainly to long term 
exposure to mercury for months. But usually the drug is given only for a week.  
In chronic studies, Histo-pathology of kidney showed normal glomeruli with 
focal cloudy swelling of the tubules. But this may be reversible, as it didn’t produce 
any significant toxic symptom in animals. Another unexplored facet, which could 
affect the efficacy and toxicity of these drugs, are drug-drug interaction that occurs 
when they are given in combination with other herbal preparations. . Although Poora 
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Parpam have metal contents far greater than the WHO limits, the toxicity of a 
preparation need not directly correlate with the metal content in the sample. The 
chemical nature of the metal, route of administration, dosage, residence time within 
the body, pharmacokinetics and dynamics, bioavailability, metabolic transformations 
of the preparation, age, gender, physiology, nature and stage of disease, and diet can 
influence the toxic manifestations of the drug. Hence a detailed study on all these 
factors is essential to answer the comprehensions raised by the usage of herbo-
metallic drugs like Poora Parpam. 
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CONCLUSION: 
 Even though the metals are purified and believed to be non-toxicaccording to 
Siddha system, this only refers to the clinical ortherapeutic dose, which isminimal. So 
over consumption due to improper medication/self-medication may lead to significant 
toxic effects. Although most of the siddha medicinalpreparations have metal contents 
far greater than the WHOlimits, the toxicity of a preparation need not directly 
correlatewith the metal content in the sample. The chemical nature ofthe metal, route 
of administration, dosage, residence timewithin the body, pharmacokinetics and 
dynamics, bioavailability,metabolic transformations of the preparation, age,gender, 
physiology, nature and stage of disease, and diet caninfluence the toxic manifestations 
of the herbo-metallicpreparations. Therefore, a careful analysisof all these parameters 
is required in order to establish the riskinvolved in a given herbo-metallic 
preparation.Most of the studies conducted thus far on mercury-based siddha medicine 
preparations in experimental animals have been short-term toxicity studies with use of 
high doses of HgS, which cannot be correlated with humans. Variations in therapeutic 
doses are recommended by practitioners for different ailments. Practioners in siddha 
medicines adopt a holistic approach to treatment and consider the physiological 
aspects of an individual along with the type of disease and stage of presentation. Diet 
restrictions also contribute toalterations in the pharmacokinetics, and thus labeling a 
traditional medicine preparation as toxic based only on the metal content seems 
inappropriate. However, in-depth and systematic investigations are not available for 
these preparations.Pre-clinical studies are needed after conversion ofthe human 
therapeutic dose to an animal dose, and bothshort-term and long-term toxicity have to 
be evaluated. 
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 Significant and substantial amount of data through thesestudies can provide a 
platform for designing human clinicaltrials. Even though cinnabar has beenused for 
centuries in traditional medicine, pharmaco-vigilancenever existed then and does not 
even prevail in the modern era. The need for patient follow-up after counselingand 
drug therapy was rare in earlier times, and even now it isnot followed stringently. 
Hence, scientific evidence is lackingto confirm the safety and efficacy of these drugs. 
No pharmco-therapeutic studies existto analyze the benefits of these drugs. 
Shortcomings inchoice of animal models and proper design of experiments toassess 
toxicity have hampered the risk assessment of thesetraditional preparations, and hence 
there is a requirement formore comprehensive studies to understand the 
ramificationsof these therapeutic processes.  
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